Compare Ascendis Pharma A/S (ASND) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Crown Castle International Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Crown Castle International Corp trades at $79.75 (market cap $34.77B). The key difference: Crown Castle International Corp is the larger of the two by market cap, and Crown Castle International Corp pays a 5.34% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CCI | |
|---|---|---|
Market Cap | $17.74B | $34.77B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $113.91 |
52-Week Low | $163.32 | $74.92 |
Enterprise Value | $18.11B | $64.59B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Crown Castle (CCI) trades at $79.66, up 3.89% today, but remains in a bearish technical trend with weak moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, while revenue declined to $4.26B in 2025. Analyst consensus is divided with a $97.33 price target, and the stock offers a 5.55% dividend yield. Recent news highlights strategic shifts to a pure-play tower focus amid leadership changes.
Outlook is cautious due to high debt levels and competitive pressures, but long-term value exists if operational improvements materialize. Key risks include interest rate sensitivity and execution challenges. Investors should weigh the dividend appeal against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
